secwatch.observer — SEC 8-K summary
======================================

Issuer:     MoonLake Immunotherapeutics (MLTX)
CIK:        0001821586
Form:       8-K
Filed at:   2026-06-09T20:30:15+00:00
Accession:  0001213900-26-066821
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MoonLake shareholders approve 5M share increase to equity plan at 2026 AGM
--------------------------------------------------------------------------

- Shareholders approved amendment to 2022 Equity Incentive Plan, adding 5,000,000 Class A shares for awards.
- Plan now includes one-year minimum vesting requirement, revised director compensation limits, and term through 2036.
- Director Spike Loy re-elected with 92.4% of votes cast; auditor Baker Tilly ratified with 99.9% support.
- Advisory vote on executive compensation passed with 98.6% of votes cast in favor.
- Total shares authorized under the plan now 9,353,948, subject to adjustment provisions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821586/000121390026066821/0001213900-26-066821-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821586/000121390026066821/ea0294064-8k_moonlake.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-066821

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer